Anzeige
Mehr »
Dienstag, 28.04.2026 - Börsentäglich über 12.000 News
Zuerst +50%… jetzt ein $20M Graphen-Deal
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

OMX Copenhagen 25 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im OMX Copenhagen 25

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
17:30KURSZIEL ANGEHOBEN bei Novo nordisk: Was Insider heute bereits wissen - Meine klare Einschätzung dazu
15:34Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?22
14:10Novo Nordisk A/S: Novo Nordisk to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity1.477Analyses of the higher dose of Wegovy (semaglutide 7.2 mg) and Wegovy pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy...
► Artikel lesen
13:39NOVO NORDISK A/S - Stabilität mit strategischer Tiefe18
13:00Tryg A/S: Tryg recognises a one-off impact of DKK 1.2bn pre-tax related to Supreme Court ruling on Danish workers' compensation113Today, the Danish Supreme Court ruled on a precedent-setting case regarding workers' compensation in Denmark, which affects the entire insurance industry as well as the State and municipalities in Denmark....
► Artikel lesen
10:27Is This Deal a Game Changer for Novo Nordisk?76
08:22Erfolg in Phase-3-Studie: Survodutid von Zealand Pharma erzielt 16,6 % Gewichtsverlust11
08:22Zealand Pharma: Survodutide erzielt 16,6 % Gewichtsverlust in Phase-III-Studie17
08:18Zealand Pharma's survodutide shows 16.6% weight loss in trial5
08:18Zealand Pharma's survodutide achieves 16.6% weight loss in trial3
08:06Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial332Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic...
► Artikel lesen
03:06Central Vietnam hub Danang deepens cooperation with Maersk on Lien Chieu port, logistics2
MoProthena Corporation plc: Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy419 Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase...
► Artikel lesen
MoMaersk lines up Med-Baltic SLA loop from Tanger Med4
MoVestas wins 186MW Quebec turbine order9
MoA.P. Møller - Mærsk A/S: Transactions in connection with share buy-back program2
MoVestas stärkt Präsenz in Nord Amerika5
MoVESTAS WIND SYSTEMS A/S: Vestas strengthens Québec presence with 186 MW order from EDF power solutions North America6
MoNovo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?68
MoMaersk reshapes Asia-Europe network with port swaps and new calls from April 20263
Weiter >>